Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to version 2.15.0 from version 2.14.4, indicating a revision in the content. The phrase 'Here’s how you know' has been modified to 'Here's how you know', which does not significantly alter the core content.SummaryDifference1.0%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 6, 2025.SummaryDifference1.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.